Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree
Novartis to pay up to $1.5B to acquire UK-based ADC specialist Myricx Bio, expanding its antibody-drug conjugate pipeline. (Source: BioSpace, 2026-07-06)
Myricx Bio
Private
Myricx Bio is a UK-based biotech developing a pipeline of antibody-drug conjugates (ADCs) for cancer using its proprietary N-myristoyltransferase inhibitor (NMTi) payload chemistry. The company raised a GBP 90M Series A and is being acquired by Novartis for up to $1.5B.
Company Info
Sector:Biotechnology / Oncology
Headquarters:London, UK
Founded:2019
Website:myricxbio.com/
Funding Round:Series A (GBP 90M)
Total Funding:GBP 90M
Funding & Investor Relations
Notable Investors
- Medicxi
- Novo Holdings
- British Patient Capital
- Cancer Research Horizons
Upcoming Milestones & Key Dates
2026 (TBD)
M&A
Novartis acquisition close
2027
Regulatory
Anticipated IND filing for MYR-001
Clinical Development Pipeline
MYR-001 (lead NMTi-ADC program)
Target: NMTi payload via tumor-targeted antibodyAdditional NMTi-ADC programs
Target: NMTi payload chemistry (platform)Platform expansion
Target: Novel NMT inhibitor payload chemistryRecent News
Leadership Team
Robin Sherrington
Chief Executive Officer
Careers & Job Openings